KRAS and cancer: Several studies have identified synthetic lethal interactors with mutant KRAS through the use of RNAi screens in human cancer cell lines [62]; unfortunately, this first generation of screens yielded only new information about the biology of mutant KRAS-harboring cells, not new therapeutic targets.